Comparison of Regenerative Changes in Peripheral Nerve Injuries Treated with a Regenerative Tube with Human Mesenchymal Cells and Platelet Rich Plasma Lysate Versus a Nerve Graft in Rats

Luis Nieto R1*, Luz Mabel Avila P2, Jenniffer P Avila G3, Pérez P4 and Santamaria E4

1Plastic Surgeon, Microsurgeon, Hand Surgeon, Professor, Pontificia Universidad Javeriana, Central Military Hospital, Colombia
2Scientific Director, Stem Medicina Regenerativa/Cryo Holdco, Colombia
3Coordinator of the Stem Regenerative Medicine Laboratory, Colombia
4Resident, Plastic Surgery, Military University Nueva Granada, Colombia

*Corresponding author: Prof. Luis Nieto, International Center of Microsurgery and Peripheral Nerve Surgery, Calle 127 A # 7-53 Of. 2001, Colombia, Tel: 57(1) 8051976; Email: lenietor@microcirugiamd.com

Abstract

Peripheral nerve injuries are a frequent pathology, and complete recovery cannot be achieved if nerve segment loss accompanied by soft tissue and concomitant bone injuries occurs.

Objective: To compare the degree of nerve regeneration in peripheral nerve lesions with loss of nervous tissue after treatment with the current "gold standard", consisting of interposition of a nerve graft, and the use of a decellularized regenerative tube including mesenchymal stem cells (MSCs) and platelet rich plasma lysate.

Materials and Methods: An experimental study was conducted in Wistar rats weighing 250-300 g divided into three groups as follows: Group 1, a 1.5-cm resection was reconstructed with a nerve graft. Group 2, a 1.5-cm resection was reconstructed with interposition of a regenerative tube. Group 3, a 1.5-cm resection was reconstructed with an interpositional regenerative tube with MSCs derived from adipose tissue and platelet-rich plasma lysate. After four weeks, a biopsy of the nerve distal to the lesion and reconstruction, along with axonal counting by hematoxylin and eosin staining, were performed to compare the three groups (STATA 12).

Results: The quantitative variables were compared among the three groups. The mean numbers of regenerated type A axons obtained in each group were as follows: Group 1: 485.1, Group 2: 14.2, and Group 3: 93.8. A statistically significant difference was found among the groups.
**Conclusions:** Improvement of axonal regeneration was observed in Group 3 compared to Group 2. This is the first experimental study to use this novel biological platform for the regeneration of peripheral nerves with xenogeneic MSCs; however, the follow-up time was limited, and the results may be improved with a longer follow-up period.

**Keywords:** Peripheral Nerve Lesion; Peripheral Nerve Regeneration; Nerve Graft; Mesenchymal Stem Cells; Platelet Rich Plasma

**Abbreviations:** MSCs: Mesenchymal Stem Cells; SC: Schwann Cells; PRP: Platelet Rich Plasma; DNAase: Deoxyribonuclease-I; PSA: Penicillin Streptomycin and Amphotericin; ISCT: International Society of Cell Therapy; GDNF: Glial Cell Line Derived Neurotrophic Factor; LIF: Leukemia Inhibitory Factor; ASCs: Adipose Derived Mesenchymal Stem Cells.

**Introduction**

In addition to timely intervention, the success of axonal regeneration after a peripheral nerve injury depends on the surgical technique, magnitude of the injury, nerve coaptation without tension, adequate coverage, and the interaction of key components at the cellular level in a synchronized manner, such as the extracellular matrix, nerve growth stimulating factors, cells that support axonal growth, and support structures that allow the directed growth of nervous tissue towards the target organs of each nerve [1]. To date, the best "scaffolding" or support to direct axonal growth has been an autologous nervous graft placed as a bridge between the section ends of the affected nerve. This technique has shown good results in approximately 60% of cases, but this percentage depends on factors such as age, comorbidities, and associated injuries in addition to the morbidity that results in the donor area and the corresponding functional loss [2]. Therefore, the replacement of autologous nerve grafts with different types of supports has been investigated with variable results in both animal models and clinical applications in humans. These results are reproducible for defects of up to 3 cm. Additionally, the support must have characteristics such as biocompatibility, biodegradability, porosity (for interaction with extracellular matrix receptors, which allows attachment of anchoring ligands, and neuronal growth factors, which favors cell proliferation), and adequate biological and mechanical properties so that the axons can grow, thus generating the necessary environment for an adequate regeneration [3,4]. Substances or cells that positively influence axonal regeneration have been used as supports, including adipose tissue mesenchymal stem cells, which have a paracrine response to the secretion of nerve growth factors [5-12], in addition to the ability to differentiate into Schwann cells (SC), which are crucial for axonal growth [13-15]. Several studies have shown that fibrin directs axonal growth during regeneration and can be obtained from platelet-rich plasma (PRP). When activated, PRP can also secrete many growth factors that promote regeneration [16]. The combination of these different therapies can improve the degree of nerve regeneration as indicated by axonal growth to the distal region of the lesion [1]. The objective of this study was to compare the regenerative changes in sciatic nerve lesions in Wistar rats (2 to 3 months of age weighing 250 to 300 g) using autologous nerve grafts versus a regenerative tube with mesenchymal cells (MSCs) derived from human adipose tissue and PRP lysate. The regenerative potential was evaluated for each group using light microscopy and axonal counting with hematoxylin and eosin staining.

**Materials and Methods**

**Animals**

Twenty-one 9-week-old Wistar rats weighing 250 to 300 g were included. The protocol and all procedures conducted on the rats were approved by the animal care committee of the National Institute of Health of Colombia. The rats were kept in polycarbonate cages. The facilities had a controlled temperature (22±2 °C), 40-65% humidity, and a 12-h light/dark cycle. Rats were fed a standard laboratory diet and allowed free access to drinking water.

**Scaffold**

Decellularized tracheas obtained from Wistar rats euthanized in other studies were used. Cleaning was performed to obtain the tracheal tissue, which was subjected to decellularization treatment with sodium deoxycholate (Sigma) at a concentration of 4% wv, 1% v/v TritonX-100, and 0.5% SDS at pH=9.0, followed by enzymatic digestion with deoxyribonuclease-I (DNAase)

Decellularization was confirmed with hematoxylin and eosin staining.

**Liposuction and Cell Culture**

The Research Ethics Committee of the Central Military Hospital approved the protocol (code 2015-052). Liposuctioned material was obtained from an individual submitted to body contouring surgery after signing informed consent. The vascular stromal fraction was obtained by enzymatic digestion with 0.75% collagenase type II. The cells were cultured in plastic T25 culture flasks (TTP) at a density of 1×106 cells/cm², with DMEM-LG supplemented with 10% FBS and 1% penicillin-streptomycin and amphotericin (PSA) at a temperature of 37 °C and an atmosphere of 5% CO₂. Once 80% confluence was obtained, the cells were enzymatically dissociated with trypsin and plated at a density of 5×10³ cells/cm². According to the MSC criteria of the International Society of Cell Therapy (ISCT), the expression of CD73 PerCP, CD90 FITC and CD105 APC (BD®) and the absence of the hematopoietic markers CD34 PE/CD45 PE and HLA-DR PE was verified, and the potential for in vitro differentiation to osteoblastic lineage was noted. The determination of phenotypic expression was conducted by flow cytometry using aFacs Canto II with Diva® software.

**Platelet-Rich Plasma Lysate**

Units obtained by direct purchase, standardized process in the "Hematológica Colombiana Foundation", for direct application in regenerative tubes.

**Surgical Procedure**

Randomization of seven rats to each of the three groups was performed, and the groups were treated as follows: Group 1 received a 1.5-cm lesion of the sciatic nerve that was reconstructed with a nerve graft, Group 2 received a 1.5-cm lesion that was reconstructed with placement of a regenerative tube, and Group 3 received a 1.5-cm lesion that was reconstructed by placement of a regenerative tube with MSCs derived from adipose tissue and resuspended in isotonic saline solution supplemented with 10% PRP lysate (Figure 1).

Follow-up was performed for 4 weeks, and at the end of this period, the experimental rats were euthanized according to standard procedures. The segment of the operated nerve distal to the site of the lesion was obtained. The 21 sciatic nerve explants were preserved in 10% formaldehyde, dehydrated in graduated methanol, rinsed three times with 100% xylene, and then embedded in paraffin for 24 h. Subsequently, the nerves were sliced with an American Optical microtome into 3-micron sections and stained with 1% toluidine blue after deparaffinization. The sections were observed under an Olympus DP80 microscope with a 10× objective, and sections were photographed at 40×magnification with a camera operated by Olympus Cell Sens Imaging software; photographs were evaluated offline using ImageJv1.45 software (NIH). Type A axons were counted, and the analysis was conducted manually and randomly by two observers who were experts in recognition of histological patterns using a double blind method [18]. From each block, three new sections of 3 microns were deparaffinized, and anti-neurofilament antibodies (Novocastra) were used for immunostaining of the axons. The axons were stained a brown color. The experiments were performed in triplicate, and data are expressed as means±standard deviations. The statistical analysis was performed with STATA 12.0 software, and a value of p<0.05 was considered statistically significant.

**Results**

**Adipose Tissue-Derived MSCs**

One line of MSCs was obtained. The cells showed adherence and fibroblast morphology in culture (Figure 2); at passage 3, the cells were cryopreserved in 12.0×10⁶ vials at a concentration of 3.0×10⁶ cells/mL. The ISCT criteria for MSCs were verified.

---

Copyright© Luis Nieto R, et al.
Figure 3 shows the immunophenotype obtained by flow cytometry evaluation of classical markers of MSCs as follows: CD105+, CD34-, CD73+, CD90+, and CD45-. In Figure 4, the osteogenic differentiation of MSCs after 20 days in culture is shown as part of the evaluation of the differentiation capacity of the obtained MSCs.

**Regenerative Tube Preparation**

The decellularized tracheas were cut to a length of 1.5 cm and a radius of 3 mm, resulting in a volume of 50 µL \((V=\pi h r^2)\). The cell concentration was \(20\times10^6\) MSCs/mL in saline with 5% PRP lysate (Figure 5).
Monitoring of Experimental Animals after Implantation

One of the 21 rats was sacrificed due to signs of stress and lack of well-being. The rat exhibited weight loss and exudation of red hematoporphyrin around the eyes. The sacrificed rat belonged to control group (Group 1) and was replaced by another animal.

Axonal Count

After examining the proximal and distal segments of each explant (Figure 6), 20 explants of sciatic nerves from experimental animals were processed and underwent immunohistochemical staining to detect microfilaments. Image processing and identification and quantification of myelinated axons (type A axons) were performed. Schwann cells, blood vessels with erythrocytes, small unmyelinated axons, and other cells were excluded (Figure 7).

After axon counting, the percentage of regeneration was determined by dividing the total number of axons of the distal nerve by the total number of axons in the proximal nerve and multiplying by 100 [19]. Statistical analysis was performed to compare the quantitative variables among the three groups, including the count of regenerated type A axons observed under microscopy. The mean numbers of type A axons per group were as follows: Group 1 (gold standard): 485.1 SD 563.6 (5-1530), Group 2 (negative control): 14.2 SD 20.4 (0-49), Group 3 (experimental group): 93.8 SD 226.4 (0-607). The Kruskal-Wallis test indicated a significant difference among the groups (p=0.017).

<table>
<thead>
<tr>
<th>Group</th>
<th>Mean # Axons</th>
<th>SD # Axons</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>485.1</td>
<td>563.6</td>
</tr>
<tr>
<td>2</td>
<td>14.2</td>
<td>20.4</td>
</tr>
<tr>
<td>3</td>
<td>93.8</td>
<td>226.4</td>
</tr>
</tbody>
</table>

Figure 5: Normality test with histogram graphic method.

Figure 6: Result counting type A axons in each group.
As an additional data, the presence of regenerated type C nerve fibers was observed in the distal sections and external epineurium (Figure 8), indicating nerve regeneration distal to the repair site. No adverse reactions to the use of stem cells or PRP lysate were observed in the mice.

**Discussion**

Peripheral nerve lesions are a frequent pathology, with an estimated incidence of 13-23 cases per 100,000 people [20]. These lesions are observed in many types of clinical situations, such as sharp injuries, car accidents, motorcycle accidents, after tumor resection, congenital malformations, and gunshot wounds, and nerve injuries are difficult repair due to injuries to the adjacent soft tissues and bones.

In these cases, therapeutic intervention is required at the appropriate time using different existing techniques. Motor and sensory recovery depends on factors such as nerve type, level, and extent of the injury, patient age, comorbidities, repair technique used, and particularly, the timing of the surgical procedure. These factors affect muscular atrophy and damage to the neuromotor plate.

Current techniques for the repair of a segmental loss of a peripheral nerve are based on the interposition of tissues or materials capable of allowing the passage of the axonal growth cone to reach the distal end of the lesion.
and regain motor or sensory function according to the type of injured nerve. The method that has shown the best results for large defects is autologous nerve grafting, but this technique has the disadvantage that morbidity occurs in the donor area of the nerve selected to serve as a bridge between the section ends of the injured nerve. The interposition of tubes consisting of different biocompatible materials has shown good results for defects of up to 3 cm in humans. Therefore, the search for methods that allow axonal growth with the minimum possible morbidity and with the largest number of axons to the target organ of the reconstructed nerve is fundamental.

Tissue engineered nerve grafts and conduits have been extensively investigated in several experimental studies, and many novel approaches utilizing acellular nerve grafts to bioengineered conduits have resulted in outcomes comparable to nerve autografts. Addition of Schwann cells or stem cells result in improved axonal regeneration compared with grafts nerve alone, and this can be further enhanced via gene therapy, supplemental neurotrophic factor delivery, Platelet Rich Plasma, and Chondroitinase-ABC, among others [21].

While many of these tissue engineered approaches have shown positive histological and electrophysiological outcomes, more studies emphasizing functional outcomes are needed to further assess clinical utility. This study demonstrated the potential of human adipose tissue MSCs to improve peripheral nerve regeneration after traumatic injury in a murine model, in which a biological scaffold engineered from decellularized trachea was used [22].

Many additional materials have been used as alternatives to nerve grafts for their ability to induce axonal regeneration across nerve gaps, include, acellular nerve grafts [23], pseudo nerves within silicon conduits [24], empty biodegradable collagen tubes [25], multiple channel conduits [26], biodegradable polyester tubes [27], synthetic hydrogel tubes [28], and biodegradable polysialic acid conduits [29]. Additional studies included the use of silicon tubes [30], empty Gore-Tex conduits [31,32], alginate gels [33], polyglycolic acid tubes filled with a collagen sponge [34], and empty conduits made of arteries [35]. Most of these techniques do not induce axons to regenerate more than 1 cm, only some induce significantly longer axon regeneration, such as alginate gels, which induce axons to regenerate across gaps up to 5.0 cm in cats, and conduits composed of muscle plus muscle-vein inducing axons to regenerate up to 5.5 cm in rats [36]. In this study we try a new natural conduit, micedescellularized trachea, with excellent results in consistency, ease of handling and good matching with segments of nerve to repair.

Several studies have investigated the influences of conduits containing various types of cells releasing different factors, for example, poly-epsilon-caprolactone conduits with a 3-dimensional matrix and Schwann cells plus leukemia inhibitory factor (LIF) [37], collagen tubes with Schwann cells [38], silicone tubes containing Schwann cells over expressing GDNF [39], a silk fibroin-based scaffold containing bone marrow mesenchymal stem cells (MSCs) [40], neural stem cells transfected to release glial cell line- derived neurotrophic factor (GDNF) and brain-derived neurotrophic factor (BDNF) [41]. Other investigations have involved testing, as well as, adipose-derived mesenchymal stem cells (ASCs) which act by accelerating the growth of blood vessels and nerve by the release of BDNF [42], conduits containing neural stem cells transfected to release GDNF and BDNF [43], the administration of growth/differentiation factor-15 [44], the topical application to crushed nerves of a 26-amino-acid fragment derived from the Clostridium botulinum C3-exoenzyme [45], dissociated Schwann cells over-expressing FGF-2 [46], collagen gel containing dissociated Schwann cells [47], Schwann cells over expressing GDNF [39], Gore-Tex tubes filled with adipose-derived stem cells [48], all them induces axon regeneration not more that 3 cm, only autologous vein grafts filled with dissociated Schwann cells induce axons to regenerate longer distances more than this distance [49], therefore we believe that the combination of factors can improve said result, and our study human mesenchymal cells and platelet rich plasma.

Multiple observations in short nerve gaps become filled with PRP, show that axons regenerate across these filled gaps, with different results in increase distance axons regenerate, PRP within collagen tubes bridging rat sciatic nerve gaps [50], a slight increase in distance axons regenerate [51] and an increase in myelin thickness [52]. However, applying PRP with mesenchymal stem cells to transected nerves induces longer distances than that induced by either alone [53], one of our objectives.

The different influences of PRP, even on the same preparation, is best explained by differences in the techniques used to prepare the PRP, because they can result in PRP with considerable differences in platelet concentration and the ratio of activated to inactivated platelets, because the influences of PRP increase with the increasing concentration of inactivated platelets [54].
Therefore, to determine reliably the influences PRP can exert on axon regeneration will require using a standardization method for preparing PRP [55]. However, it will still be essential to determine whether PRP has similar effects on different preparations in the same animal model and between different animal models.

The mechanism of action of MSCs is associated with their neuroprotective abilities via paracrine secretion, stimulation of cell division, retardation of the onset of apoptosis, and immunomodulatory effects. The production of neurotrophic substances [56], such as FGF, ciliary neurotrophic factor, BDNF, and GDNF, and the high levels of NGF-b, present in MSCs, improve axon regeneration and remyelination [57-61].

The possible role of PRP to induce nerve regeneration investigated in animal studies have shown the benefit of PRP application in peripheral nerve anastomoses, in particular in models of sciatic and facial nerve lesions. Farrag, et al. [62] have shown that PRP improved functional outcomes after facial nerve anastomosis in rats. In addition, Giannessi, et al. [63] have shown an improvement in sciatic nerve regeneration after suturing a PRP-enriched membrane at the anastomosis site. PRP may increase the thickness of the myelin sheaths and nerve fiber density through surrounding SC recruitment and angiogenesis activation.

The combination of MSCs and PRP lysate can improve axonal regeneration due to targeting by fibrin and increased quantities and numbers of growth factors present in the plasma.

While more experimental studies are needed, the continued research in the pathophysiology of peripheral nerve injury and the advances in tissue engineering techniques will one day result in a viable alternative to autografts for different lengths nerve defects.

Conclusions

This is the first experimental study worldwide to use this novel biotechnological platform to evaluate the regeneration of peripheral nerves with xenogeneic MSCs, demonstrating the usefulness and efficacy of this technique in the reconstruction of peripheral nerve lesions. The main weakness of the study is the short observation period, although if we take into account that the axonal growth in the animal model used is 3 to 5 mm/day, for the nervous defect made the time is sufficient for the axonal count in the distal to the lesion, main objective of the investigation, requiring longer periods of observation in new studies to demonstrate recovery of function and electromyographic changes.

This experimental study may facilitate new clinical studies to evaluate the effectiveness of this technique in other animal models and humans, which may generate new therapeutic options to reduce the morbidity associated with nerve reconstruction with autologous grafts.

Funding

Funding resources for this study came from research funds of the Central Military Hospital.

Conflict of Interest

The authors have no conflicts of interest to declare.

Acknowledgments

The Colombian National Institute of Health, Dr. Alejandra Muñoz Suarez and Dr. Ricardo Vanegas Romero and Basemedica SAS for their contributions in carrying out this work.

References


